Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 11/20 | 0.46 |
| ▸ | CTSB | P07858 | 8/20 | 0.46 |
| ▸ | CTSS | P25774 | 7/20 | 0.46 |
| ▸ | CTSK | P43235 | 3/20 | 0.46 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6741608 | 1.00 | CTSL (0.46) | CTSLCTSBCTSSCTSKCTSF | |
| SCHEMBL7658551 | 0.95 | CTSL (0.52) | CTSLCTSBCTSSCTSKCTSF | |
| SCHEMBL6061943 | 0.94 | CTSB (0.48) | CTSLCTSBCTSSCTSKCTSF | |
| SCHEMBL7682674 | 0.94 | CTSB (0.46) | CTSLCTSBCTSSCTSKCTSF | |
| SCHEMBL6062326 | 0.93 | CTSB (0.45) | CTSLCTSBCTSSCTSKCTSF | |
| SCHEMBL6062502 | 0.93 | CTSB (0.45) | CTSLCTSBCTSSCTSKCTSF | |
| SCHEMBL6063237 | 0.92 | CTSB (0.44) | CTSLCTSBCTSSCTSKCTSF | |
| SCHEMBL6063285 | 0.91 | CTSB (0.42) | CTSLCTSBCTSSCTSKCTSF | |
| SCHEMBL1557816 | 0.91 | CTSB (0.42) | CTSLCTSBCTSSCTSKCTSF | |
| SCHEMBL6063030 | 0.91 | CTSB (0.45) | CTSLCTSBCTSSCTSKCTSF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200197334-A1 | Paediatric Compositions For Treating Multiple Sclerosis | NOVARTIS AG (CH) | 2020-06-25 | — | — | US | disclosed |
| EP-3545953-A1 | PAEDIATRIC COMPOSITIONS FOR TREATING1 MULTIPLE SCLEROSIS | Novartis AG (CH) | 2019-10-02 | — | — | EP | disclosed |
| US-20170333368-A1 | Paediatric Compositions For Treating Multiple Sclerosis | NOVARTIS AG (CH) | 2017-11-23 | — | — | US | disclosed |
| US-20170128389-A1 | Paediatric Compositions For Treating Multiple Sclerosis | NOVARTIS AG (CH) | 2017-05-11 | — | — | US | disclosed |
| US-20160206574-A1 | Paediatric Compositions For Treating Multiple Sclerosis | NOVARTIS AG (CH) | 2016-07-21 | — | — | US | disclosed |
| EP-3011958-A1 | PAEDIATRIC COMPOSITIONS FOR TREATING MULTIPLE SCLEROSIS | Novartis AG (CH) | 2016-04-27 | — | — | EP | disclosed |
| US-20160022611-A1 | Paediatric Compositions For Treating Multiple Sclerosis | KOVARIK JOHN M (CH) | 2016-01-28 | — | — | US | disclosed |
| EP-2255798-B1 | FTY720 for use in the treatment of optic neuritis | NOVARTIS AG (CH) | 2014-12-24 | — | — | EP | disclosed |
| US-20140271541-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS IN THE TREATMENT OF DEMYELINATING DISORDERS | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20130230489-A1 | Paediatric Compositions For Treating Multiple Sclerosis | KOVARIK JOHN M (CH) | 2013-09-05 | — | — | US | disclosed |
| US-20120225031-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS IN THE TREATMENT OF DEMYELINATING DISORDERS | FOSTER CAROLYN ANN (AT) | 2012-09-06 | — | — | US | disclosed |
| EP-2303250-A1 | PAEDIATRIC COMPOSITIONS FOR TREATING1 MULTIPLE SCLEROSIS | Novartis AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| EP-2255798-A2 | Sphingosine-1-phosphate receptor agonists for use in the treatment of optic neuritis | Novartis AG (CH) | 2010-12-01 | — | — | EP | disclosed |
| EP-2251007-A2 | Sphingosine-1-phosphate (S1P) receptor agonists for use in the treatment of demyelinating diseases | Novartis AG (CH) | 2010-11-17 | — | — | EP | disclosed |
| US-20090324542-A1 | optic neuritis; fingolimod or 2-amino-2-{2-[4-(1-oxo-5-phenylpentyl)phenyl]ethyl}propane-1,3-diol or salts as SP1 agonist | FOSTER CAROLYN ANN | 2009-12-31 | — | — | US | disclosed |
| WO-2009155475-A1 | PAEDIATRIC COMPOSITIONS FOR TREATING1 MULTIPLE SCLEROSIS | NOVARTIS AG (CH) | 2009-12-23 | — | — | WO | disclosed |
| US-20060046979-A1 | Combination therapy of sphingosine-1-phosphate (S1P) receptor agonist and coagent for treating demylination disease | FOSTER CAROLYN A | 2006-03-02 | — | — | US | disclosed |
| EP-1575576-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004028521-A2 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS IN THE TREATMENT OF DEMYELINATING DISORDERS | NOVARTIS AG (CH) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130230489-A1 | Paediatric Compositions For Treating Multiple Sclerosis | SMN1; SMN2, PMP22, MYT1 | CTSL 2951/4885CTSB 1192/4885CTSS 2364/4885 |
| US-20090324542-A1 | optic neuritis; fingolimod or 2-amino-2-{2-[4-(1-oxo-5-phenylpentyl)phenyl]ethyl}propane-1,3-diol or salts as SP1 agonist | SP1, S1PR2, S1PR1 | CTSL 1980/4885CTSB 3963/4885CTSS 4227/4885 |
| US-20160206574-A1 | Paediatric Compositions For Treating Multiple Sclerosis | SMN1; SMN2, PMP22, CFTR | CTSL 2725/4885CTSB 986/4885CTSS 2185/4885 |
| US-20120225031-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS IN THE TREATMENT OF DEMYELINATING DISORDERS | S1PR1, S1PR2, S1PR4 | CTSL 2043/4885CTSB 2719/4885CTSS 3240/4885 |
| US-20160022611-A1 | Paediatric Compositions For Treating Multiple Sclerosis | SMN1; SMN2, PMP22, CFTR | CTSL 2725/4885CTSB 986/4885CTSS 2185/4885 |
| US-20170333368-A1 | Paediatric Compositions For Treating Multiple Sclerosis | SMN1; SMN2, PMP22, CFTR | CTSL 2855/4885CTSB 1079/4885CTSS 2266/4885 |
| US-20060046979-A1 | Combination therapy of sphingosine-1-phosphate (S1P) receptor agonist and coagent for treating demylination disease | S1PR1, S1PR4, S1PR2 | CTSL 1290/4885CTSB 1516/4885CTSS 1619/4885 |
| US-20200197334-A1 | Paediatric Compositions For Treating Multiple Sclerosis | SMN1; SMN2, PMP22, CFTR | CTSL 2725/4885CTSB 986/4885CTSS 2185/4885 |
| US-20140271541-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS IN THE TREATMENT OF DEMYELINATING DISORDERS | S1PR1, S1PR2, S1PR4 | CTSL 2043/4885CTSB 2719/4885CTSS 3240/4885 |
| US-20170128389-A1 | Paediatric Compositions For Treating Multiple Sclerosis | SMN1; SMN2, PMP22, CFTR | CTSL 2725/4885CTSB 986/4885CTSS 2185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.